Breast cancer survivors’ opinion on personalizing endocrine therapy and developing informative tools

Archive ouverte

Rassy, Elie | Benvenuti, Chiara | Akla, Sarra | Di Meglio, Antonio | Martin, Elise | Havas, Julie | Rieutord, André | Combarel, David | Fasse, Léonor | Scotté, Florian | Guéroult Accolas, Laure | Jacob, Guillemette | Bergougnoux, Anne | Delaloge, Suzette | Vaz-Luis, Ines | Pistilli, Barbara

Edité par CCSD ; Nature -

International audience. Abstract Understanding breast cancer survivors’ perspectives is critical to personalizing endocrine therapy (ET) in the adjuvant setting. A nationwide survey among breast cancer survivors was proposed in France, in collaboration with patient advocacy organizations, to assess their perspectives on personalizing ET and developing dedicated informative tools. This survey explored patients’ preferences regarding ET intake schedule, formulation, presentation (color, taste, shape, size, design, and packaging), combination with agents targeting ET-related adverse events, and a mobile application to support them during ET. Of the 1103 individuals who started the survey, 939 (85.1%) were eligible for enrollment and completed the survey. The majority of the participants considered that a personalized ET should take into consideration the intake schedule ( n = 974, 90.7%) and swallowable tablet formulation ( n = 606, 64.5%), without a preference for ET presentation ( n = 619; 65.9%). The majority of the participants expressed a willingness to participate in a potential clinical trial evaluating the combination of ET with agents targeting ET-related adverse events at the start of ET ( n = 752, 80.1%) or in the case of major ET-related adverse events ( n = 778, 82.8%). The primary considerations were to have an uncompromised ET efficacy and a guaranteed reduction of adverse events. Last, a dedicated mobile application was considered helpful by 665 participants (70.8%). Informative tools should focus on the recommendations for dealing with adverse events ( n = 593, 63.2%), the impact on the patient’s daily life ( n = 515, 54.9%), benefits ( n = 504, 53.7%), and adverse events ( n = 494, 52.6%) of ET. This survey paves the way for multimodal strategies that can include a personalized ET (e.g., ET in combination with agents targeting ET-related adverse events) and dedicated mobile applications to ultimately improve adherence.

Suggestions

Du même auteur

Implementing a PROACTive Care Pathway to Empower and Support Survivors of Breast Cancer

Archive ouverte | Franzoi, Maria, Alice | CCSD

International audience. PURPOSE Optimal comprehensive survivorship care is insufficiently delivered. To increase patient empowerment and maximize the uptake of multidisciplinary supportive care strategies to serve a...

A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design

Archive ouverte | Di Meglio, Antonio | CCSD

International audience. Abstract Background Elevated body mass index (BMI) represents a risk factor for cancer-related fatigue (CRF). Weight loss interventions are feasible and safe in cancer survivors, leading to i...

Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue

Archive ouverte | Lapidari, Pietro | CCSD

International audience. BACKGROUND: Despite the questionable effectiveness of oral complementary and alternative medicine (OCAM) in relieving cancer-related symptoms, including fatigue (CRF), many patients use it ai...

Chargement des enrichissements...